AR046076A1 - Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida - Google Patents

Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida

Info

Publication number
AR046076A1
AR046076A1 ARP040102543A ARP040102543A AR046076A1 AR 046076 A1 AR046076 A1 AR 046076A1 AR P040102543 A ARP040102543 A AR P040102543A AR P040102543 A ARP040102543 A AR P040102543A AR 046076 A1 AR046076 A1 AR 046076A1
Authority
AR
Argentina
Prior art keywords
precursor cells
population
oligodendrocyte precursor
obtaining
procedures
Prior art date
Application number
ARP040102543A
Other languages
English (en)
Inventor
Hiroshi Okazaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR046076A1 publication Critical patent/AR046076A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Abstract

Población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos con estado de desarrollo sincronizado y procedimientos para obtener una población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos. Otros procedimientos incluyen procedimientos para mantener y almacenar una población homogénea de células precursoras de oligodendrocitos durante períodos prolongados sin cambio en las características de las células y procedimientos para diferenciar células precursoras de oligodendrocitos. La población fenotípicamente homogénea autorenovante de células precursoras de oligodendrocitos o población homogénea de oligodendrocitos pueden ser útil para tratar a un paciente que tiene un desorden o condición del sistema nervioso central. Reivindicación 1: Procedimiento para obtener una población homogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo sincronizado, caracterizado porque comprende cultivar una población heterogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo no sincronizado, en un medio que comprende una cantidad de factor de crecimiento de fibroblasto (FGF) eficaz para inducir una etapa sincronizada de desarrollo y en donde dicho cultivo se lleva a cabo en ausencia sustancial de factor de crecimiento derivado de plaquetas (FCDP), obteniendo así dicha población homogénea de células precursoras de oligodendrocitos que tienen un estado de desarrollo sincronizado.
ARP040102543A 2003-07-18 2004-07-16 Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida AR046076A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48793303P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
AR046076A1 true AR046076A1 (es) 2005-11-23

Family

ID=34079394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102543A AR046076A1 (es) 2003-07-18 2004-07-16 Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida

Country Status (13)

Country Link
US (1) US20060172415A1 (es)
EP (1) EP1646711A4 (es)
JP (1) JP2007530001A (es)
KR (1) KR20060037346A (es)
CN (1) CN1833021A (es)
AR (1) AR046076A1 (es)
AU (1) AU2004257000B2 (es)
BR (1) BRPI0412715A (es)
CA (1) CA2532216A1 (es)
MX (1) MXPA05014161A (es)
SG (1) SG144166A1 (es)
TW (1) TW200510537A (es)
WO (1) WO2005007797A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086761A2 (en) * 2005-02-11 2006-08-17 Elan Pharmaceuticals, Inc. Methods of identifying genes which modulate myelination
DK1904113T3 (en) * 2005-06-23 2016-03-21 Tissuegene Inc NEURO PROTECTIVE EFFECTIVE CONNECTION
ES2323913B1 (es) * 2006-03-17 2010-05-14 Universidad De Salamanca (Titular Al 65%) Efecto mitogeno de sonic hedgehog (shh) sobre precursores de oligodendrocitos y su uso en enfermedades desmielinizantes.
EP2247747B1 (en) * 2008-01-30 2018-03-21 Geron Corporation Method for producing a cell culture article
KR101809863B1 (ko) 2008-01-30 2017-12-15 아스테리아스 바이오세라퓨틱스, 인크. 줄기 세포 유래 심근세포 배양용 합성 표면
WO2009097421A1 (en) * 2008-01-30 2009-08-06 Geron Corporation Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
WO2010054307A1 (en) * 2008-11-07 2010-05-14 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
NO2499238T3 (es) * 2009-11-12 2018-01-27
CN101735983B (zh) * 2009-12-29 2011-07-27 中国人民解放军第三军医大学 少突胶质前体细胞的分离纯化方法
ES2375860B8 (es) * 2010-03-31 2013-06-10 Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin) Método para la obtención de células precursoras de oligodendrocitos.
CA2838486A1 (en) * 2011-08-07 2013-02-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
KR101409336B1 (ko) 2012-02-15 2014-06-27 중앙대학교 산학협력단 희돌기교전구세포를 유효성분으로 포함하는 중추신경계 질환의 치료용 조성물
EP2831222B1 (en) * 2012-03-27 2018-12-26 Okinawa Institute of Science and Technology Graduate University Neuronal culture medium and method for producing in vivo-like and enhanced synaptogenesis neuron model
US10180423B2 (en) * 2012-12-19 2019-01-15 The Regents Of The University Of California Micropillar arrays for assaying myelination
CN103388007B (zh) * 2013-07-25 2016-08-24 宗兆文 一种利用真皮来源的间充质干细胞制备组织工程脊髓的方法
JP6844953B2 (ja) * 2015-04-22 2021-03-17 公益財団法人東京都医学総合研究所 アルツハイマー病研究を標的にしたグリア細胞システム
CN105062956B (zh) * 2015-08-21 2018-02-09 北京市虹天济神经科学研究院 人嗅粘膜嗅鞘细胞分离、传代、冻存、分化技术
CN105695409B (zh) * 2016-03-22 2019-09-27 中国人民解放军第二军医大学 一种裸鼹鼠少突胶质前体细胞培养方法
US11920155B2 (en) 2016-03-30 2024-03-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
WO2018053210A1 (en) * 2016-09-14 2018-03-22 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
CN109722418B (zh) * 2017-10-29 2023-01-03 复旦大学 一种获取和纯化新生小鼠少突胶质前体细胞的方法
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
CN113481161A (zh) * 2021-07-30 2021-10-08 四川省医学科学院·四川省人民医院 一种培养基及少突胶质祖细胞的诱导培养方法以及应用
CN115340982A (zh) * 2022-08-23 2022-11-15 徐州医科大学 一种分离并纯化新生小鼠皮质区少突胶质前体细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6361996B1 (en) * 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Also Published As

Publication number Publication date
EP1646711A2 (en) 2006-04-19
AU2004257000B2 (en) 2011-07-21
WO2005007797A3 (en) 2006-05-11
EP1646711A4 (en) 2008-03-19
CN1833021A (zh) 2006-09-13
WO2005007797A2 (en) 2005-01-27
AU2004257000A1 (en) 2005-01-27
SG144166A1 (en) 2008-07-29
TW200510537A (en) 2005-03-16
KR20060037346A (ko) 2006-05-03
MXPA05014161A (es) 2006-05-25
US20060172415A1 (en) 2006-08-03
BRPI0412715A (pt) 2006-09-26
JP2007530001A (ja) 2007-11-01
CA2532216A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
AR046076A1 (es) Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
Kuehnle et al. The therapeutic potential of stem cells from adults
CN103396993B (zh) 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
WO2007030469A3 (en) Transplantable cell growth niche and related compositions and methods
ECSP056027A (es) Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21.
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
DK1651758T3 (da) Fremgangsmåde tl fremstilling af L-lysin eller L-threonin ved anvendelse af Escherichia bakterier med svækket æblesyreenzymaktivitet
BRPI0517514A8 (pt) Vesículas bacterianas imunogênicas com proteínas da membrana externa
Horwitz Stem cell plasticity: a new image of the bone marrow stem cell
ES2167461T3 (es) Modelos in vitro de funcion y disfuncion del sistema nervioso central.
FR2812004B1 (fr) Milieux de culture pour fecondation in vitro, ou pour la culture de follicules, cellules germinales males ou embryons
Oliver Adult renal stem cells and renal repair
AR023987A1 (es) Vides resistentes a un patogeno
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
AU757036B2 (en) Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies
TW200617165A (en) Process for preparing a conditioned medium of astrocyte-like cells
AU2002250934A1 (en) Bioartificial primarily vascularized tissue matrix, bioartificial primarily vascularized tissue, method for the production thereof and use of the same
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
WO2005054447A3 (en) Müller stem cells
ATE384121T1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
WO2002063938A3 (en) Production and use of dopaminergic cells to treat dopaminergic deficiencies
Guo et al. Effects of cerebral microvascular endothelial cells and vascular endothelial growth factor on the proliferation and differentiation of NSCs: a comparative study
Nicholas et al. Sphingolipids in the Human Cornea, to boldly go where no one has gone before

Legal Events

Date Code Title Description
FB Suspension of granting procedure